Crinetics Pharmaceuticals 的新 CAH 治疗药物 atumelnant 获得 FDA 的孤儿药称号。 Crinetics Pharmaceuticals' new CAH treatment, atumelnant, receives FDA's Orphan Drug Designation.

克里尼特克制药公司已获得FDA的孤儿药物指标,用于其新治疗方法,阿图梅伦,用于先天性上腺增生 (CAH). Crinetics Pharmaceuticals has received Orphan Drug Designation from the FDA for its new treatment, atumelnant, for congenital adrenal hyperplasia (CAH). 这种一次日间口服药物是首次针对这种罕见状况的ACTH受体使用这种药物。 This once-daily oral medication is the first of its kind targeting the ACTH receptor for this rare condition. 该指定支持发展稀有疾病的治疗方法,提供潜在的财政奖励和市场独家经营。 The designation supports the development of treatments for rare diseases, offering potential financial incentives and market exclusivity.